Home > Back to Publisher > Report Information

Global Schizophrenia Prevalence, Companies Analysis & Drugs Forecast (2010 - 2015)

Renub Research
August 10, 2011
65 Pages - SKU: RNBR6484186

Abstract Table of Contents Search inside this report Related Reports

Countries covered: Global

Global Schizophrenia Prevalence, Companies Analysis & Drugs Forecast (2010 - 2015)

Schizophrenia - Market Overview

Schizophrenia is a mental disorder characterized by disintegration of thought processes and of emotional responsiveness. It most commonly manifests as auditory hallucinations, paranoid or bizarre delusions, or disorganized speech and thinking, or lack of concentration and motivation and it is accompanied by significant social or occupational dysfunction. However with proper medication this disease can be contained to a great extent and Schizophrenia patients can lead a normal healthy life style.

At present lot of drugs for Schizophrenia are available in the market. From the introduction of Clozapine in 1991.Since, 1960, the first atypical antipsychotic to treat schizophrenia, the growth of this class has been rapid. Zyprexa, Seroquel, Risperdal, Abilify, Geodon are the blockbuster drug which has changed the dynamics of the schizophrenia market. But the major worry for the manufactures of these drugs is that by 2011 and 2012 almost all the major blockbuster drugs are going off-patent.

However, depot formulation is the emerging segment which has long term chances of success. The pipeline drug like Lurasidone, Staccato, Cariprazine, Pimavanserin have the comparable efficacy and a similar mechanism of action to that of the existing brands which will enter the market by 2011.

Additional Information

Report Details

“Global Schizophrenia Prevalence, Companies Analysis & Drugs Forecast (2010 - 2015)” report published by Renub Research provides an in-depth analysis of the past, present and future prospects. The report has been researched at source globally and features latest available data covering:

Global Schizophrenia Market has been covered from 2004-2019
Global Schizophrenia patients in 7 countries
Top 10 Schizophrenia Drug Brands (Zyprexa, Seroquel, Risperdal, Abilify, Geodon, Lonasen, Serdolect, Invega, Fanapt, Saphris) data analysis of Past, Present and Future Market
Top 3 Schizophrenia Depot Formulations Brands (Risperdal Consta, Invega Sustenna, Relprevv) data analysis of Past, Present and Future Market
Pipeline Developmental Agents (Lurasidone, Staccato, Cariprazine, Pimavanserin) Future Trends Analyis
Key Companies Strengths and Weakness analysis in Global Schizophrenia

Research Highlights

The prevalence of Schizophrenia in United States is expected to reach nearly 4 Million by 2020
From 2012 onwards Schizophrenia market is expected to show a decline
Zyprexa is the most successful product in the history of neuroscience
Abilify hit blockbuster sales in 2006 and it is anticipated that sales will cross US$ 2.5 Billion by 2014.
Risperdal Consta is the blockbuster injectable form of medicines and predicted that the sale will cross US$ 2 Billion by 2014
Lurasidone, Staccato, Cariprazine, Pimavanserin are the pipepline drug which will be launched by 2011

Key Companies Analyzed

This section covers the business description, Strengths and Weakness of major players in Global Schizophrenia Market. The key players analyzed in this section are - Eli Lilly and Company, AstraZeneca, Johnson & Johnson, Bristol-Myers Squibb and Pfizer.

Data Sources

Information and data in this report has been collected from various printable and non-printable sources like Trade Journals, White papers, Online paid databases, News websites, Government Agencies, Magazines, Newspapers and Trade associations.

1. Executive Summary
2. Global Schizophrenia Market Past, Present & Future Trend
3. Prevalence of Schizophrenia in Top 7 Countries: 3.1 United States of America; 3.2 Japan; 3.3 Germany; 3.4 France; 3.5 Italy; 3.6 United Kingdom; 3.7 Spain
4. Global - Top 10 Schizophrenia Drug Brands Market Performance: 4.1 Zyprexa (Olanzapine); 4.2 Seroquel (Quetiapine); 4.3 Geodon; 4.4 Risperdal (Risperidone); 4.5 Lonasen; 4.6 Serdolect; 4.7 Abilify (Aripiprazole); 4.8 Invega (Paliperidone); 4.9 Fanapt (iloperidone); 4.10 Saphris (Asenapine)
5. Global - Top 3 Schizophrenia Depot Formulations Brand Market Performance: 5.1 Risperdal Consta (Risperidone); 5.2 Invega Sustenna (Paliperidone Palmitate); 5.3 Relprevv/Zyphdera (Olanzapine LAI)
6. Pipeline Developmental Agents - Future Trends: 6.1 Lurasidone; 6.2 Staccato (Loxapine Inhalation); 6.3 Cariprazine (RGH-188); 6.4 Pimavanserin
7. Key Companies: 7.1 Eli Lilly and Company; 7.2 Astrazeneca; 7.3 Johnson & Johnson; 7.4 Bristol-Myers Squibb; 7.5 Pfizer; 7.5.1 Business Description; 7.5.2 Strength & Weaknesses

List of Figure:

Figure 2 1: Global - Schizophrenia Market (Billion US$), 2004 - 2010

Figure 2 2: Global - Forecast for Schizophrenia Market (Billion US$), 2011 - 2019

Figure 3 1: USA - Number of Patients with Schizophrenia Disease (Million), 2005 - 2010

Figure 3 2: Japan - Number of Patients with Schizophrenia Disease (Million), 2005 - 2010

Figure 3 3: Germany - Number of Patients with Schizophrenia Disease (Million), 2005 - 2010

Figure 3 4: France - Number of Patients with Schizophrenia Disease (Million), 2005 - 2010

Figure 3 5: Italy - Number of Patients with Schizophrenia Disease (Million), 2005 - 2010

Figure 3 6: UK - Number of Patients with Schizophrenia Disease (Million), 2005 - 2010

Figure 3 7: Spain - Number of Patients with Schizophrenia Disease (Million), 2005 - 2010

Figure 4 1: Global - Zyprexa Drug Sales (Million US$), 1999 - 2010

Figure 4 2: Global - Forecast for Zyprexa Drug Sales (Million US$), 2011 - 2015

Figure 4 3: Global - Seroquel Drug Sales (Million US$), 1999 - 2010

Figure 4 4: Global - Forecast for Seroquel Drug Sales (Million US$), 2011 - 2015

Figure 4 5: Global - Geodon Drug Sales (Million US$), 1999 - 2010

Figure 4 6: Global - Forecast for Geodon Drug Sales (Million US$), 2011 - 2015

Figure 4 7: Global - Risperdal Drug Sales (Million US$), 1999 - 2010

Figure 4 8: Global - Forecast for Risperdal Drug Sales (Million US$), 2011 - 2015

Figure 4 9: Global - Lonasen Drug Sales (Million US$), 2008 - 2010

Figure 4 10: Global - Forecast for Lonasen Drug Sales (Million US$), 2011 - 2014

Figure 4 11: Global - Serdolect Drug Sales (Million US$), 2006 - 2010

Figure 4 12: Global - Forecast for Serdolect Drug Sales (Million US$), 2011 - 2015

Figure 4 13: Global - Abilify Drug Sales (Million US$), 2002 - 2010

Figure 4 14: Global - Forecast for Abilify Drug Sales (Million US$), Q1-2011, 2011 - 2015

Figure 4 15: Global - Invega Drug Sales (Million US$), 2008 - 2010

Figure 4 16: Global - Forecast for Invega Drug Sales (Million US$), 2011 - 2015

Figure 4 17: Global - Forecast for Fanapt Drug Sales (Million US$), 2011 - 2015

Figure 4 18: Global - Forecast for Saphris Drug Sales (Million US$), 2011 - 2015

Figure 5 1: Global - Risperdal Consta Drug Sales (Million US$), 2006 - 2010

Figure 5 2: Global - Forecast for Risperdal Consta Drug Sales (Million US$), 2011 - 2015

Figure 5 3: Global - Invega Sustenna Drug Sales (Million US$), 2009 - 2010

Figure 5 4: Global - Forecast for Invega Sustenna Drug Sales (Million US$), 2011 - 2015

Figure 5 5: Global - Relprevv/Zyphdera Drug Sales (Million US$), 2009 - 2010

Figure 5 6: Global - Forecast for Relprevv/Zyphdera Drug Sales (Million US$), 2011 - 2015

Figure 6 1: Global - Forecast for Lurasidone Drug Sales (Million US$), 2011 - 2017

Figure 6 2: Global - Forecast for Staccato Drug Sales (Million US$), 2010 - 2017

Figure 6 3: Global - Forecast for Cariprazine Drug Sales (Million US$), 2013 - 2017

Figure 6 4: Global - Forecast for Pimavanserin Drug Sales (Million US$), 2014 - 2017

List of Tables:

Table 3 1: USA - Forecast for Number of Patients with Schizophrenia Disease (Million), 2010 - 2015, 2020, 2025, 2030, 2035, 2040, 2045, 2050

Table 3 2: Japan - Forecast for Number of Patients with Schizophrenia Disease (Million), 2010 - 2015, 2020, 2025, 2030, 2035, 2040, 2045, 2050

Table 3 3: Germany - Forecast for Number of Patients with Schizophrenia Disease (Million), 2011 - 2015, 2020, 2025, 2030, 2035, 2040, 2045, 2050

Table 3 4: France - Forecast for Number of Patients with Schizophrenia Disease (Million), 2011 - 2015, 2020, 2025, 2030, 2035, 2040, 2045, 2050

Table 3 5: Italy - Forecast for Number of Patients with Schizophrenia Disease (Million), 2011 - 2015, 2020, 2025, 2030, 2035, 2040, 2045, 2050

Table 3 6: UK - Forecast for Number of Patients with Schizophrenia Disease (Million), 2010 - 2015, 2020, 2025, 2030, 2035, 2040, 2045, 2050

Table 3 7: Spain - Forecast for Number of Patients with Schizophrenia Disease (Million), 2011 - 2015, 2020, 2025, 2030, 2035, 2040, 2045, 2050

Table 4 1: Eli Lilly - Challenges to Zyprexa Patents in a number of Countries outside the U.S (2007, 2008 & 2010)

Table 7 1: Eli Lilly and Company - Key Financial (Million US$), 2008 - 2010

Table 7 2: Astrazeneca - Key Financial (Million US$), 2008 - 2010

Table 7 3: Johnson & Johnson - Key Financial (Million US$) 2008 - 2010

Table 7 4: Bristol-Myers Squibb - Key Financial (Million US$) 2008 - 2010

Table 7 5: Global - Comparison Chart of Patent Expiry Date of different Blockbuster Drugs

Table 7 6: Pfizer - Key Financial (Million US$), 2008 - 2010

More Global CNS/Neurology Reports

Traumatic Brain Injury Global Clinical Trials Review, H1, 2012 by GlobalData
Traumatic Brain Injury Global Clinical Trials Review, H1, 2012 Summary GlobalData's clinical trial report, “Traumatic Brain Injury Global Clinical Trials Review, H1, 2012 provides data on the ...

Tension -Type Headache Global Clinical Trials Review, H1, 2012 by GlobalData
Tension -Type Headache Global Clinical Trials Review, H1, 2012 Summary GlobalData's clinical trial report, “Tension -Type Headache Global Clinical Trials Review, H1, 2012 provides data on the ...

Cluster Headache Syndrome Global Clinical Trials Review, H1, 2012 by GlobalData
Cluster Headache Syndrome Global Clinical Trials Review, H1, 2012 Summary GlobalData's clinical trial report, “Cluster Headache Global Clinical Trials Review, H1, 2012 provides data on the Cluster ...

Cerebral Infarction (Brain Infarction) Global Clinical Trials Review, H1, 2012 by GlobalData
Cerebral Infarction (Brain Infarction) Global Clinical Trials Review, H1, 2012 Summary GlobalData's clinical trial report, “Cerebral Infarction (Brain Infarction) Global Clinical Trials Review, H1, 2012 provides data ...

Brain Ischemia Global Clinical Trials Review, H1, 2012 by GlobalData
Brain Ischemia Global Clinical Trials Review, H1, 2012 Summary GlobalData's clinical trial report, “Brain Ischemia Global Clinical Trials Review, H1, 2012 provides data on the Brain Ischemia ...

See all reports like this >>

Global Schizophrenia Prevalence, Companies Analysis & Drugs Forecast (2010 - 2015)

Share this report

Other tasks

Research Assistance

Related Markets

CNS/Neurology Reports

Free Alert Me service